Johnson & Johnson’s oncology treatment regimen, Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib), is now approved as a first-line therapy, the drugmaker said Aug. 20.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA approves first-line treatment for lung cancer
